Evidence map›Paper›PMID 42708004›Full record

ArticleTheranostics2026

Unravelling the

Mariam-Eleni Oraiopoulou, Thierry L Lefebvre, Eleftheria Tzamali, Thomas R Else, Ian G Cannell, Lorna C Wright, Ellie V Bunce, Cara Brodie, Paul W Sweeney, Luca Porcu and 4 more

Abstract read
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mariam-Eleni OraiopoulouCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Thierry L LefebvreCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Eleftheria TzamaliInstitute of Computer Science, Foundation for Research and Technology - Hellas, Heraklion, Greece.
Thomas R ElseCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Ian G CannellCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Lorna C WrightCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Ellie V BunceCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Cara BrodieCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Paul W SweeneyCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Luca PorcuCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Dominique-Laurent CouturierMedical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK.
Vangelis SakkalisInstitute of Computer Science, Foundation for Research and Technology - Hellas, Heraklion, Greece.
Gregory J HannonCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.
Sarah E BohndiekCancer Research UK Cambridge Institute (CRUK CI), University of Cambridge, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasculogenic mimicry describes the ability of cancer cells to acquire endothelial properties, forming vessel-like channels that facilitate tumour blood supply and can drive resistance to anti-angiogenic therapies. While the molecular drivers have been well-explored in cell cultures and biopsies, vasculogenic mimicry remains a clinical blind spot as no methods exist to detect and monitor such vascular networks non-invasively Methods: Here, we introduce a "topology-first" framework to define vasculogenic mimicry biomarkers and elucidate its spatiotemporal dynamics using label-free optical and photoacoustic imaging across scales. Using graph theory analysis, we decoded the unique vascular architecture of 4T1 and 4T1-T murine breast cancer models in response to anti-angiogenic treatment with Axitinib. Results: We found stable meshed networks Conclusions: Our results provide the first evidence that vasculogenic mimicry features can be mapped non-invasively through topology, offering a potential future companion diagnostic and method to guide the development of next-generation, multi-target anti-vascular therapeutics.

Indexed as

Breast NeoplasmsNeovascularization, PathologicAngiogenesis InhibitorsAnimalsAxitinibCell Line, TumorDisease Models, AnimalFemaleHumansMiceMice, Inbred BALB CPhotoacoustic TechniquesAngiogenesis InhibitorsAxitinibanti-angiogenic therapycancerimaging biomarkerstumour vascular networkvasculogenic mimicry

Identifiers

PMID42708004
PMCPMC13549142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.